|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bansal N, Herzog TJ, Shaw RE, Burke WM,
Deutsch I and Wright JD: Primary therapy for early-stage cervical
cancer: Radical hysterectomy vs radiation. Am J Obstet Gynecol.
201:485.e1–485.e9. 2009. View Article : Google Scholar
|
|
3
|
Kosmas C, Mylonakis N, Tsakonas G, Vorgias
G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N,
Akrivos T, et al: Evaluation of the paclitaxel-ifosfamide-cisplatin
(TIP) combination in relapsed and/or metastatic cervical cancer. Br
J Cancer. 101:1059–1065. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colombo N, Carinelli S, Colombo A, Marini
C, Rollo D and Sessa C: Cervical cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii27–vii32. 2012.PubMed/NCBI
|
|
5
|
Castellsagué X, Díaz M, de Sanjosé S,
Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS,
Snijders PJ, et al International Agency for Research on Cancer
Multicenter Cervical Cancer Study Group: Worldwide human
papilloma-virus etiology of cervical adenocarcinoma and its
cofactors: Implications for screening and prevention. J Natl Cancer
Inst. 98:303–315. 2006. View Article : Google Scholar
|
|
6
|
Wang Z and Cai H, Lin L, Tang M and Cai H:
Upregulated expression of microRNA-214 is linked to tumor
progression and adverse prognosis in pediatric osteosarcoma.
Pediatr Blood Cancer. 61:206–210. 2014. View Article : Google Scholar
|
|
7
|
Tamura M, Uyama M, Sugiyama Y and Sato M:
Canonical Wnt signaling activates miR-34 expression during
osteoblastic differentiation. Mol Med Rep. 8:1807–1811. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis-Dusenbery BN and Hata A: Mechanisms
of control of microRNA biogenesis. J Biochem. 148:381–392.
2010.PubMed/NCBI
|
|
9
|
Chan JK, Kiet TK, Blansit K, Ramasubbaiah
R, Hilton JF, Kapp DS and Matei D: MiR-378 as a biomarker for
response to anti-angiogenic treatment in ovarian cancer. Gynecol
Oncol. 133:568–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma J, Lin J, Qian J, Qian W, Yin J, Yang
B, Tang Q, Chen X, Wen X, Guo H, et al: MiR-378 promotes the
migration of liver cancer cells by down-regulating Fus expression.
Cell Physiol Biochem. 34:2266–2274. 2014. View Article : Google Scholar
|
|
11
|
Browne G, Dragon JA, Hong D, Messier TL,
Gordon JA, Farina NH, Boyd JR, VanOudenhove JJ, Perez AW, Zaidi SK,
et al: MicroRNA-378-mediated suppression of Runx1 alleviates the
aggressive phenotype of triple-negative MDA-MB-231 human breast
cancer cells. Tumour Biol. 37:8825–8839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang
L, Li G, Chen HH and Li XP: MicroRNA-378 functions as an onco-miR
in nasopharyngeal carcinoma by repressing TOB2 expression. Int J
Oncol. 44:1215–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qian J, Lin J, Qian W, Ma JC, Qian SX, Li
Y, Yang J, Li JY, Wang CZ, Chai HY, et al: Overexpression of
miR-378 is frequent and may affect treatment outcomes in patients
with acute myeloid leukemia. Leuk Res. 37:765–768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang Y, Liu X and Wang Y: MicroRNA-378
regulates neural stem cell proliferation and differentiation in
vitro by modulating Tailless expression. Biochem Biophys Res
Commun. 466:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng J, Xie Z, Cheng L, Zhang Y, Chen J,
Yu H, Li Z and Kang H: Paired design study by real-time PCR:
miR-378* and miR-145 are potent early diagnostic biomarkers of
human colorectal cancer. BMC Cancer. 15:1582015. View Article : Google Scholar
|
|
16
|
Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang
W, Ma Y and Xiao H: Genome-wide microRNA profiles identify miR-378
as a serum biomarker for early detection of gastric cancer. Cancer
Lett. 316:196–203. 2012. View Article : Google Scholar
|
|
17
|
Fedorko M, Stanik M, Iliev R,
Redova-Lojova M, Machackova T, Svoboda M, Pacik D, Dolezel J and
Slaby O: Combination of MiR-378 and MiR-210 serum levels enables
sensitive detection of renal cell carcinoma. Int J Mol Sci.
16:23382–23389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katoh M: Molecular cloning and
characterization of ST7R (ST7-like, ST7L) on human chromosome 1p13,
a novel gene homologous to tumor suppressor gene ST7 on human
chromosome 7q31. Int J Oncol. 20:1247–1253. 2002.PubMed/NCBI
|
|
19
|
Kirikoshi H and Katoh M: Expression of
ST7R (ST7-like, ST7L) in normal tissues and cancer. Int J Oncol.
21:193–196. 2002.PubMed/NCBI
|
|
20
|
Chen L, Zhang A, Li Y, Zhang K, Han L, Du
W, Yan W, Li R, Wang Y, Wang K, et al: MiR-24 regulates the
proliferation and invasion of glioma by ST7L via β-catenin/Tcf-4
signaling. Cancer Lett. 329:174–180. 2013. View Article : Google Scholar
|
|
21
|
Yang Z, Wang XL, Bai R, Liu WY, Li X, Liu
M and Tang H: miR-23a promotes IKKα expression but suppresses ST7L
expression to contribute to the malignancy of epithelial ovarian
cancer cells. Br J Cancer. 115:731–740. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhuang L, Wang X, Wang Z, Ma X, Han B, Zou
H, Wu Z, Dong S, Qu Z, Zang Y, et al: MicroRNA-23b functions as an
oncogene and activates AKT/GSK3β/β-catenin signaling by targeting
ST7L in hepatocellular carcinoma. Cell Death Dis. 8:e28042017.
View Article : Google Scholar
|
|
23
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park H, Lee MJ, Jeong JY, Choi MC, Jung
SG, Joo WD, Lee C and An HJ: Dysregulated microRNA expression in
adenocarcinoma of the uterine cervix: Clinical impact of
miR-363-3p. Gynecol Oncol. 135:565–572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li ZZ, Shen LF, Li YY, Chen P and Chen LZ:
Clinical utility of microRNA-378 as early diagnostic biomarker of
human cancers: A meta-analysis of diagnostic test. Oncotarget.
7:58569–58578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang N, Zhong J, Han S, Li Y, Yin Y and
Li J: MicroRNA-378 alleviates cerebral ischemic injury by
negatively regulating apoptosis executioner caspase-3. Int J Mol
Sci. 17:E14272016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen QG, Zhou W, Han T, Du SQ, Li ZH,
Zhang Z, Shan GY and Kong CZ: MiR-378 suppresses prostate cancer
cell growth through downregulation of MAPK1 in vitro and in vivo.
Tumour Biol. 37:2095–2103. 2016. View Article : Google Scholar
|
|
29
|
Li B, Wang Y, Li S, He H, Sun F, Wang C,
Lu Y, Wang X and Tao B: Decreased expression of miR-378 correlates
with tumor invasiveness and poor prognosis of patients with glioma.
Int J Clin Exp Pathol. 8:7016–7021. 2015.PubMed/NCBI
|
|
30
|
Li W, Yang W, Liu Y, Chen S, Chin S, Qi X,
Zhao Y, Liu H, Wang J, Mei X, et al: MicroRNA-378 enhances
inhibitory effect of curcumin on glioblastoma. Oncotarget. May
16–2017.Epub ahead of prin. View Article : Google Scholar
|
|
31
|
Farazi TA, Juranek SA and Tuschl T: The
growing catalog of small RNAs and their association with distinct
Argonaute/Piwi family members. Development. 135:1201–1214. 2008.
View Article : Google Scholar : PubMed/NCBI
|
